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Abstract
Introduction: Interleukin (IL)-17F plays a critical role in the pathophysiology of
asthma. However, the precise role of IL-17F in airway smooth muscle cells
(ASMCs) and its regulatory mechanisms remain to be defined. Therefore, we
sought to investigate the expression of IL-6 by IL-17F and the involvement
of transforming growth factor b-activated kinase 1 (TAK1) and nuclear factor
(NF)-kB by in ASMCs.
Methods: ASMCs were cultured in the presence or absence of IL-17F. The
expression of IL-6 gene and protein was analyzed using real-time PCR and ELISA,
and the activation of TAK1 andNF-kBwas detected byWestern blotting. The effect
of TAK1 inhibitor 5Z-7-oxozeaenol and NF-kB inhibitor BAY 11-7082 on the
expression of IL-6 was investigated. Finally, the short interfering RNAs (siRNAs)
targeting TAK1 and a subunit of NF-kB, p65 were transfected into ASMCs.
Results: The expression of IL-6 gene and protein was significantly induced by
IL-17F. IL-17F activated TAK1 and NF-kB in ASMCs. Transfection of siRNAs
targeting TAK1 abolished IL-17F-induced phosphorylation of p65. Both
5Z-7-oxozeaenol and BAY 11-7082 significantly inhibited IL-17F-induced IL-6
production in a dose-dependent manner. Similarly, transfection of the cells with
siRNAs targeting TAK1 and p65 inhibited the expression of IL-6.
Conclusions:Collectively, these results provided evidence supporting the potential
importance of the Th17-ASMCs crosstalk via the IL-17F-IL-6 axis in airway
inflammation and as a candidate pharmacological target for airway inflammatory
diseases such as asthma.
Introduction
Asthma is characterized by the association of airway
inflammation, airway obstruction, increased airway hyper-
reactivity, and remodeling. Airway smooth muscle is
believed to contribute to the pathophysiology of asthma
including direct causation of airflow obstruction via
contraction. However, recent emerging evidences have
demonstrated that airway smooth muscle plays a pivotal
role in regulation of allergic airway inflammation via their
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ability to produce many inflammatory molecules including
IL-6 [1, 2]. IL-6 is known to be a potential contributor of
asthma pathogenesis. Intranasal administration of a block-
ing anti-IL-6 receptor antibody in a mouse model of asthma
has been shown to be able to decrease eosinophilia, the
expression of Th2 cytokines, and airway hyperresponsive-
ness [3]. Hence, IL-6 might be a suitable target for a new
approach to asthma therapy. But, how ASMCs-derived pro-
inflammatorymediators such as IL-6 are regulated remain to
be fully defined. Thus, further understanding of the
mechanisms through which ASMCs-derived IL-6 is regu-
lated would be important to uncover the pathogenic
mechanisms of asthma.
Discovery of a novel molecule involving allergic airway
inflammation and identification of its signaling mechanisms
might help to clarify the pathogenesis of asthma. We and
other groups cloned human IL-17F gene [4–6]. The IL-17F
gene is evidently upregulated in the airway from patients
with asthma [4]. Moreover, we have demonstrated that a
single nucleotide polymorphism in IL-17F gene that results
in a loss-of-function mutation is inversely related to asthma
risk and is a natural IL-17F antagonist [7, 8]. These findings
indicate that IL-17F is one of the important cytokines
involved in the etiology of asthma. In addition, the level of
IL-17F expression is correlated with the disease severity of
asthma [9]. Although IL-17F is able to act several cell types to
induce various cytokines, the role of IL-17F in ASMCs
remains unclear [10–12]. ASMCs express a receptor for
IL-17F, a heterodimer of IL-17RA and IL-17RC [13].
However, its intercellular signaling pathway is not well
defined. Recent studies have shown that transforming
growth factor b-activated kinase-1 (TAK1), a member of
the mitogen-activated protein kinase kinase kinase family, is
a pivotal signaling molecule leading to the activation of the
transcription factors nuclear factor-kappa B (NF-kB) [14,
15]. TAK1 regulates the pathogenesis of innate and adaptive
immunity including airway inflammation. In bronchial
epithelial cells, TAK1 mediates the signaling of environmen-
tal stimuli such as respiratory viral infection which is a major
cause of acute exacerbations [16]. However, the inducible
factors of TAK1 in ASMCs remain unclear. In this study, we
demonstrated, for the first time, that IL-17F is able to
activate the TAK1-NF-kB signaling pathway to induce IL-6
expression in ASMCs.
Methods
Cell culture
ASMCswere purchased fromLonza (Walkersville,MD,USA)
and cultured in SmBM medium with SmGM-2 SingleQuots
(Lonza, Tokyo, Japan) containing insulin, fibroblast growth
factor, gentamicin, 5% fetal bovine serum, and epidermal
growth factor at 378C with 5% CO2 in humidified air.
Confluent cells at passages 2–4 were used.
Analysis of IL-6 gene expression
Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Chatsworth, CA, USA) from 1 106 ASMs at 4, 12, 24, and
48 h after stimulation with 10 and 100 ng/mL of IL-17F
(R&D Systems, Tokyo, Japan). cDNAs were synthesized
from 1mg of total RNA using the ReverTra Ace qPCR RT Kit
(TOYOBO, Tokyo, Japan), followed by real-time PCR. The
sequences of primers for IL-6 are as follows: forward, 50-AA
AGAGGCACTGGCAGAAAA-30, reverse, 50-CACCAGGCA
AGTCTCCTCAT-30; G3PDH: forward, 50-ACCACAGTC-
CATGCCATCAC-30, reverse, 50-TCCACCACCCTGTTGCT
GTA-30. Real-time PCR was done using a THUNDERBIRD
SYBR qPCR Mix (TOYOBO), gene-specific primers, and an
ABI 7500 real-time PCR system. The data were shown as fold
induction relative to the control group. The values are
expressed as mean SEM (n¼ 6 experiments).
Analysis of IL-6 protein production
Cell supernatants in ASMCs were harvested from cultures in
the absence or presence of 10 and 100 ng/mL of IL-17F at 4,
12, 24, and 48 h. Alternatively, the cells were also stimulated
by 100 ng/mL of IL-17A (R&D Systems) for 24 h. IL-6
protein levels in the supernatants of IL-17F-stimulated cells
were determined with a commercially available ELISA kit
(R&D Systems) according to the manufacturer’s instruction,
and expressed as the amount recovered per 106 cells. The
values are expressed as mean SEM (n¼ 6 experiments).
Detection of TAK1 and NF-kB by Western blotting
For analysis of activation of TAK1 and NF-kB, ASMCs were
treated with IL-17F (100 ng/mL) and in some cases with or
without transfection with the siRNAs targeting TAK1, p65
and control using HiPerFect Transfection Reagent (Qiagen).
The total cellular extracts (1 106 cell equivalents/lane) were
subjected to 7.5–15% Tris-glycine gel electrophoresis (DRC,
Tokyo, Japan), followed by transfer onto polyvinylidene
difluoride membranes (Bio-Rad, Tokyo, Japan). The Abs
used were anti-TAK1 Ab, anti-phospho-TAK1 Ab, anti-
phospho-p65 Ab (Cell Signaling Technology, Danvers, MA,
USA), anti-p65 (Rel A) Ab (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
Effect of TAK1 inhibition on the expression of IL-6
For analysis of the involvement of TAK1, ASMCs were
treated in the presence or absence of a TAK1 inhibitor, 5Z-7-
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Oxozeaenol (Sigma–Aldrich, Tokyo, Japan) at varying
doses, and a vehicle control, 0.1% DMSO, for 3 h before
treatment with IL-17F (100 ng/mL). The supernatants were
harvested at 48 h after stimulation for analyses with ELISA.
IL-6 protein levels in the supernatants were determined as
described above. These values are expressed as mean SEM
(n¼ 6 experiments). Simultaneously, pre-designed siRNAs
for TAK1 (Santa Cruz Biotechnology) and control siRNAs
(Ambion, Tokyo, Japan) were used. The siRNA transfection
into ASMCs by HiPerFect Transfection Reagent (Qiagen)
was performed according to the manufacturer’s instruction.
The supernatants were then harvested at 24 h after
stimulation with 100 ng/mL of IL-17F and subjected to
analysis by ELISA, respectively. IL-6 protein levels in
the supernatants are expressed as mean SEM (n¼ 6
experiments).
Effect of NF-kB inhibition on the expression of IL-6
For the analysis of involvement of NF-kB, ASMCs were
treated in the presence or absence of a NF-kB inhibitor, BAY
11-7082 (Calbiochem, Tokyo, Japan) at varying doses, and a
vehicle control, 0.1% DMSO, for 1h before treatment with
IL-17F (100 ng/mL). The supernatants were harvested at 24 h
after stimulation for analyses with ELISA. IL-6 protein levels
in the supernatants were determined as described above.
These values are expressed as mean SEM (n¼ 6 experi-
ments). Pre-designed siRNAs for p65 (Santa Cruz Biotech-
nology) were also used for transfection into ASMCs as
described above. The supernatants were then harvested at
24 h after stimulation with 100 ng/mL of IL-17F and
subjected to analysis by ELISA, respectively. IL-6 protein
levels in the supernatants are expressed as mean SEM
(n¼ 6 experiments).
Data analysis
The statistical significance of differences was determined by
analysis of variance (ANOVA). The values are expressed as
mean SEM from independent experiments. Any difference
with P-values less than 0.05 was considered significant.
When ANOVA indicated a significant difference, the Scheffe
F-test was used to determine the difference between groups.
Results
Expression of IL-6 gene and protein
A 100 ng/mL of IL-17F significantly induced IL-6 gene
expression when compared with control at 4, 12, and 24 h
time points (Fig. 1A). IL-17F significantly induced its
expression in a dose-dependent manner at 4 and 12 h after
stimulation. The levels of IL-6 protein production were
analyzed by ELISA (Fig. 1B). IL-6 protein were detected in
unstimulated cells, but its levels in supernatants were
significantly increased, peaking at 24 h time point, in ASMCs
stimulated with IL-17F when compared with control at every
time point. Similarly, IL-17F significantly induced IL-6
production in a dose-dependent manner at 12, 24, and 48 h
after stimulation. Other IL-17 cytokine family, IL-17A
showed the similar potency to induce IL-6 expression as
IL-17F at 24 h time point (Fig. 1C).
Activation of TAK1 by IL-17F
TAK1 was equally detected at all-time points (Fig. 2). In
contrast, a transient phosphorylation of TAK1 was seen on
stimulation of the cells with IL-17F, reaching the maximum
at 10–20min after stimulation and returned to baseline levels
by 120min in ASMCs.
Effect of TAK1 inhibition on IL-17F-induced IL-6
expression
Pretreatment of the cells with 0.1, 0.5, and 1.0mM of TAK1
inhibitor, 5Z-7-Oxozeaenol significantly blocked IL-17F-
induced IL-6 production in a dose-dependent manner, while
3-h pretreatment of the cells with vehicle alone (DMSO) did
not affect its production in ASMCs (Fig. 3A). To further
confirm whether TAK1 plays a role in IL-17F-induced IL-6
expression, total TAK1 expression was diminished in the
cells by transfecting with siRNAs targeting TAK1 (Fig. 3B).
As shown in Figure 4C, IL-6 production induced by IL-17F
was significantly inhibited in cells transfected with siRNAs
targeting TAK1 when compared with cells transfected with a
control siRNAs.
Activation of NF-kB (p65) by IL-17F
A subunit of NF-kB, p65, was detected at all-time points
(Fig. 4A). Phosphorylation of p65 was evidently detected at
10–60min, and returned to baseline levels by 120min in
IL-17F-stimulated ASMCs (Fig. 4A). To establish the
interrelationship between TAK1 and NF-kB, the cells were
transfected with siRNAs targeting TAK1 before the
stimulation with IL-17F. Transfection with the siRNAs
clearly diminished the activation of p65 induced by IL-17F,
while transfection of control siRNAs did not affect the
activation of p65 (Fig. 4B).
Effect of NF-kB inhibition on IL-17F-induced IL-6
expression
Pretreatment of ASMCs for 1h with 0.5, 1.0 and 5.0mM of a
NF-kB inhibitor, BAY 11-7082 significantly decreased the levels
of IL-17F-induced IL-6 protein production in a dose-dependent
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manner, while 1h pretreatment of the cells with vehicle alone
(DMSO) did not affect IL-6 production (Fig. 5A). Finally, to
further confirm whether NF-kB plays a role in IL-17F-induced
IL-6 expression, it was found thatwhenNF-kBp65was knocked
down in the cellswith siRNAs(Fig. 5B), IL-6production induced
by IL-17F was significantly inhibited when compared with cells
transfected with control siRNAs (Fig. 5C).
Discussion
In this study, we demonstrated that IL-17F significantly
induced the expression of IL-6 in AMSCs via the activation of
TAK1-NF-kB signaling pathway. These findings indicate the
likely importance of the IL-17F-IL-6 axis in airway
inflammation as a consequence of the Th17-ASMC crosstalk.
Current study demonstrated that IL-17F signal mediates
TAK1-NF-kB pathway. This suggests that this signaling
pathway is pivotal for IL-17F-induced IL-6 expression in
Figure 2. Activation of TAK1 by IL-17F in ASMCs. The cells were
incubated with IL-17F (100 ng/mL) for different time points as indicated.
Western blotting analysis was performed with Abs against total (t)-TAK1
and phosphorylated (p)-TAK1 as indicated. These results shown are
representative of three separate experiments.
Figure 1. The expression of IL-6 gene and protein by IL-17F in ASMCs. (A) Gene expression of IL-6 by IL-17F. Real-time PCR was performed as described
in Materials andMethods. ASMCs were stimulated with IL-17F (100 ng/mL) for 4, 12, and 24h (n¼ 6). P< 0.05 versus medium control. (B) IL-6 protein
expression by IL-17F. ELISA was performed as described in Materials and Methods. The cells were stimulated with IL-17F (100ng/mL) for 4–48h (n¼ 6).
P< 0.05 versus medium control. #P< 0.05 versus 10 ng/mL of IL-17F-stimulated cells. (C) IL-6 protein levels induced by IL-17A and IL-17F in
supernatants (n¼ 6). The cells were stimulated with 100ng/mL of IL-17A or IL-17F for 24 h (n¼ 6). P< 0.05 versus medium control.
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ASMCs. TAK1 is for the first time, identified as a novel
signaling molecule involved in the function of IL-17F.
Consistent with the previous studies, TAK1 is located
upstream of NF-kB, since a TAK1 inhibitor 5Z-7-
Oxozeaenol diminished the phosphorylation of NF-
kB [15]. Moreover, the activation of NF-kB is crucial for
IL-6 expression by IL-17F, since NF-kB inhibitor and the
specific siRNAs abrogated its expression. Recent reports
demonstrated that TAK1 is clearly involved in the pathogen-
esis of airway inflammation. TAK1 activation in bronchial
epithelial cells was induced by several inflammatory stimuli
such as RS virus, Pseudomonas aeruginosa and diesel
exhaust particles that are able to exacerbate airway inflam-
mation [16–18]. Interestingly, TAK1 is involved in steroid
responsiveness in asthma [19]. Blocking of TAK1
recovers cellular response to steroids in the presence of
pathogenic bacteria via the regulation ofMAPKphosphatase-
1activation. However, the functional role of TAK1 in ASMCs
still remains. It is known that TAK1 contributes to cigarette
smoke-induced IL-8 production and the causing of airway
remodeling through the induction of growth factor-induced
proliferation of ASMCs [20, 21]. Here, we reported that IL-
17F induced phosphorylation of TAK1, indicating that TAK1
is a potentially pharmacological target for the IL-17F-
mediated airway inflammatory diseases. However, the
inhibitors and siRNAs targeting TAK1 or NFkB-p65 did
not completely inhibit IL-17F-induced IL-6 expression in this
study. This suggests that the involvement of other signaling
molecules. Further study is needed to identify novel signaling
pathways of IL-17F and its functional impact on IL-6
expression.
Figure 4. Activation of NF-kB by IL-17F. (A) Kinetic activation of NF-kB by
IL-17F in ASMCs. The cells were incubated with IL-17F (100 ng/mL) for
different time points as indicated. Western blotting was performed with
Abs against total (t)-p65 and phosphorylated (p)-p65. (B) Effect of siRNAs
targeting TAK1 on IL-17F-induced phosphorylation of p65. The cells were
transfected with siRNAs targeting TAK1 or control siRNAs, and then
ASMCs were stimulated with IL-17F for 30min.Western blotting analysis
was performed with Abs against t-p65 and p-p65. The results shown are
representative of three separate experiments.
Figure 3. Effect of the inhibition for TAK1 on IL-6 expression. ASMCs were pretreated with 5Z-7-Oxozeaenol (0.1, 0.5, and 1.0mM) for 3 h before the
24 h-stimulation of IL-17F (100 ng/mL), and then IL-6 protein levels in supernatants were measured by ELISA. The values are expressed as means SEM
(n¼ 6). P< 0.05 versus IL-17F-stimulated cells in the absence of the inhibitor. P< 0.05 versus the presence of individual inhibitor. (B) The validation of
blocking by siRNAs targeting TAK1 was performed by Western blotting. These results shown are representative of three separate experiments. (C) After
transfection of the siRNAs, ASMCs were stimulated with IL-17F (100ng/mL) for 24 h. The levels of IL-6 protein production in the supernatants were
measured by ELISA. The values are expressed as means SEM (n¼ 6). P< 0.05 versus IL-17F-stimulated cells transfected with a control siRNA.
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IL-17F shows several distinctive features of asthma such
as airway remodeling, goblet cell hyperplasia, and
increasing airway hyperreactivity. Overexpression of IL-
17F following Ag challenge in the airway of mice resulted
in the induction of goblet cell hyperplasia and, gene
expression of MUC5AC and significant increase in airway
hyperreactivity [22]. These findings suggest that IL-17F
can provide an additive effect on antigen-induced allergic
inflammatory responses. In addition, IL-17F is associated
with airway neutrophilia. Although neutrophilic inflam-
mation is one of the features of severe asthma, its precise
mechanism has not been clarified. Overexpression of IL-
17F in the mouse airways results in an increased number of
neutrophils in bronchoalveolar lavage fluid (BALF) [22,
23]. Interestingly, IL-17F is more involved in airway
neutrophilic inflammation to Aspergillus oryzae when
compared with IL-17A [24]. Moreover, IL-17F is able to
induce CXC chemokines, such as IL-8, ENA-78, and
GROa, that are potent chemoattractants for neutrophils [4,
25]. Hence, Neutrophil recruitment into the airway may be
regulated via, at least partially, IL-17F-induced CXC
chemokines. IL-17F-producing cells are known to come
from many cell types, such as bronchial epithelial cells,
basophils, mast cells, gdT cells, CD8þT cells, and Th17
cells [4, 26–28]. Especially, Th17 cells are deeply involved
in the pathogenesis of a diverse group of immune-
mediated diseases, including asthma [29]. Th17 cells are
the major cell source of IL-17F, and our current study
demonstrated that IL-17F could induce IL-6 expression.
IL-6 is necessary for Th17 development through the
induction of a transcriptional factor, retinoic acid
receptor-related orphan nuclear receptor (RORgt) [30].
Although the cell source of IL-6 in airway inflammation has
not been fully understood, the current study suggests that IL-6
is derived from, at least partially, ASMCs in response to IL-
17F. Taken together, it is possible that as a mode of the Th17-
ASMC crosstalk, IL-17F-induced IL-6 further promotes Th17
cell differentiation, which, in turn, establishes a positive
feedback loop resulting in the amplification of the Th17
response. Further in vivo study is needed to clarify the
importance of the IL-17F/IL-6 axis in asthma.
The role of ASMCs in the pathogenesis of airway
inflammation has become increasingly clear. ASMCs are
able to induce a wide range of cytokines and chemokines that
orchestrate airway inflammation [31]. However, the
functional role of IL-17F in ASMCs has not been clarified.
A few studies have demonstrated that IL-17F induces the
migration and proliferation of ASMCs [13, 32]. These
findings suggest the involvement of IL-17F in airway
remodeling. Interestingly, unlike IL-17A, IL-17F did not
affect ASM cell contraction [33]. However, the reason of this
difference has not been dissolved yet. Although both IL-17A
and IL-17F bind to same receptor the heterodimeric
complex of IL-17RA and IL-17RC, the binding affinity of
Figure 5. Effect of NF-kB inhibition on IL-17F-induced IL-6 expression. (A) ASMCswere pretreatedwith NF-kB inhibitor, BAY 11-7082 for 1 h before the
24 h-stimulation of IL-17F (100ng/mL), and then IL-6 protein levels in supernatants were measured by ELISA. The values are expressed as means SEM
(n¼ 6). P< 0.05 versus IL-17F-stimulated cells in the absence of the inhibitor. P< 0.05 versus the presence of individual inhibitor. (B) The validation of
blocking by siRNAs targeting p65 was performed by Western blotting. These results shown are representative of three separate experiments. (C) After
transfection of the siRNAs, ASMCs were stimulated with IL-17F (100ng/mL for 24 h. The levels of IL-6 protein production in the supernatants were
measured by ELISA. The values are expressed as means SEM (n¼ 6). P< 0.05 versus IL-17F-stimulated cells transfected with control siRNAs.
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IL-17A and IL-17F is quite different [34]. IL-17RA effectively
binds to IL-17A. In contrast, it binds to IL-17F with
extremely lower affinity. The relative binding affinity of
IL-17F to IL-17RC is more potent than to IL-17RA. These
findings may affect their different biological activity for ASM
cell contraction. Further study is needed in the future.
On the other hand, IL-6 is a key factor in the
pathophysiologic events of asthma [35]. Increased levels of
IL-6 are observed in serum, BALF, and induced sputum from
asthmatic patients. The levels of IL-6 in sputum and serum
are inversely correlated with lung function in asthmatic
patients [36, 37]. Besides inducing Th17 cell development,
IL-6 is a critical regulator of promoting IL-4 production
during Th2 differentiation, inhibiting Th1 differentiation,
and is a co-factor in IL-4-dependent IgE synthesis [38, 39].
Moreover, IL-6 is involved in airway mucus hypersecretion
that is one of the features of asthma [40]. Hence, ASMCs are
important target cells for IL-17F, and contribute to the
pathogenesis of allergic airway inflammation, at least
partially, via the induction of IL-6 expression.
In conclusion, we demonstrated that IL-17F activates
TAK1-NF-kB signaling pathway to induce IL-6 expression.
IL-17F/IL-6 axismight be involved in the pathophysiology of
allergic airway inflammation, and targeting IL-17F and its
signaling pathways could be a novel strategy for asthma.
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